Skip to main content
. Author manuscript; available in PMC: 2012 Jan 18.
Published in final edited form as: Neuroscience. 2011 Jun 13;190:339–345. doi: 10.1016/j.neuroscience.2011.06.004

Fig. 2.

Fig. 2

T1DM increases serum HMGB and MMP-9 levels after stroke. Niaspan treatment decreases serum HMGB and MMP-9 levels in T1DM-MCAo rats. Using Western blot assay, the data show that T1DM-MCAo rats significantly increases serum HGMB1 and MMP-9 levels compared to WT-MCAo rats (P<0.05). Niaspan treatment significantly decreases serum HGMB1 and MMP-9 levels in T1DM-MCAo rats compared to non-Niaspan treatment T1DM-MCAo rats (P<0.05). n=4/group. * P<0.05 vs. WT-MCAo control. # P<0.05 vs. T1DM-MCAo control.